BioEP™ - decision support that unlocks the potential of EEG with mathematical modelling

BioEP uses the power of mathematical modelling to unlock greater potential of EEG by increasing its diagnostic yield. BioEP analyses EEG for the presence of data features and brain network based markers that are shown to be elevated in people with epilepsy.

Do you have epilepsy or suspected epilepsy?
Find out how BioEP can help

What is BioEP™ and how does it work?

BioEP™ is a clinical decision support system that analyses EEG data and indicates whether the analysis of a patient’s EEG is supportive of epilepsy or unsupportive, supporting the case for a differential diagnosis.

BioEP uses routinely collected EEG recordings gathered as part of the patient’s diagnostic journey, and computationally analyses the EEG for the presence of data features and novel brain network-based markers (i.e. digital Biomarkers of EPilepsy) that are shown in published literature to be elevated in people with epilepsy. See our research to find out more about the markers that BioEP uses.

The BioEP analysis helps to differentiate between brain networks typical in people with and without epilepsy. The BioEP report therefore, acts as an additional piece of evidence to support clinical diagnostic and ‘next steps’ decisions .

How BioEP works in clinic

A clinician uploads an EEG. The BioEP score is calculated and a report is made available to the clinic. The report is used alongside other clinical information to support clinical decision making.

How long BioEP takes

BioEP takes just 15 minutes to calculate from as little as 15 minutes of EEG. The average clinical diagnosis of epilepsy takes over a year. Whilst differential conditions such as NEAD take as long as 7 years.

BioEP is UKCA-marked Class I medical device.

Epilepsy is hard to diagnose and difficult to treat

In current clinical practice, EEGs are used to search for the presence of abnormalities indicative of epilepsy (typically interictal spikes or discharges). These electrographic patterns, alongside behavioural manifestations, serve as the main diagnostic marker for epilepsy and signify an increased tendency for the brain to generate seizures. However, 70% of EEGs contain no such features and are considered clinically negative.

Because the majority of EEGs do not capture any epileptiform activity, multiple EEG tests are often required. This reduces service capacity in neurophysiology and neurology centres, is inconvenient for the individual undergoing diagnosis and results in delays and uncertainty. It takes on average longer than a year to diagnose epilepsy. Delays in diagnosis cause major impacts on quality and length of life.

There are no robust clinical markers of prognosis. Doctors rely on patient self-reports. Information gathered by patients about their condition is often missing or fallible. There is at present neither the capacity nor a marker to monitor treatment progress strategically. As a result, fewer than 50% of people are seizure free after one year on medication. Management is effectively trial and error, with doctors relying on patients to report their response to treatment. We are looking to change that.

of EEGs are inconclusive
misdiagnosis rate

How BioEP™ can improve clinical care pathways

Benefits at a glance

Supports diagnosis from first EEG

We don’t need to wait to observe epileptiform activity. We can use apparently normal, background EEG to identify the likelihood of future seizures. This means we can support a diagnosis from the first EEG that BioEP™ is run on. Using BioEP™ can therefore reduce diagnostic delay and improve quality of life for patients.

Currently in research

Informing optimal care pathway

BioEP™ can expedite a diagnosis of epilepsy or in some cases, a differential diagnosis such as Non-Epileptic Attack Disorder (NEAD). In doing so, patients can be transferred to the next step of the care pathway more quickly. If BioEP is highly suggestive of epilepsy, clinicians can refer with urgency for more tests. Conversely, if BioEP is highly unsuggestive of epilepsy, clinicians may refer patients faster to an alternative optimal care pathway such as neurophsychiarty in the case of NEAD. Being able to expedite patients through the pathway towards treatment reduces the numbers of patients presenting in A&E with seizures and results in better quality of life for patients.

Indicating response to treatment

Once medication is started, BioEP™ can be performed regularly to capture the effect of treatment response. This objective approach to prognosis reduces the uncertainty about whether medication is working and may speed up the trial-and-error process of identifying the optimal medication for a person with epilepsy. This could have a radical impact for people with epilepsy and the healthcare system improving lives and reducing costs. It could also help understand the efficacy of new compounds that could support the development of new Anti-Seizure medication.

BioEP™ regulatory compliance

BioEP is a Class 1 Medical Device under 93/42/EEC Medical Device Directive (MDD) and is both UKCA & CE marked. Neuronostics are Cyber Essentials certified and registered with ISO for data protection

Our Partners

Interested in finding out more or seeing a demo?